Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 10/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | F13A1 | P00488 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15270538 | 0.93 | TSHR (0.50) | TSHRRXFP1TBXAS1RAB9AKDM4E | |
| SCHEMBL3515895 | 0.86 | FFAR1 (0.55) | TSHRMAPTRXFP1RAB9AKDM4E | |
| SCHEMBL9657521 | 0.79 | FFAR1 (0.44) | MAPTRXFP1TBXAS1ALDH1A1FFAR1 | |
| SCHEMBL22197961 | 0.79 | RAB9A (0.40) | TSHRRAB9AKDM4EALDH1A1 | |
| SCHEMBL5250071 | 0.78 | CYP4F2 (0.48) | MAPTTBXAS1RAB9AALDH1A1 | |
| SCHEMBL4768617 | 0.78 | ADRA2A (0.39) | TSHRTBXAS1RAB9AKDM4EALDH1A1 | |
| SCHEMBL9082300 | 0.76 | KCNH2 (0.48) | MAPTRAB9AKDM4EALDH1A1 | |
| SCHEMBL9083017 | 0.76 | KCNH2 (0.48) | MAPTRAB9AKDM4EALDH1A1 | |
| SCHEMBL22748383 | 0.76 | KCNH2 (0.48) | MAPTRAB9AKDM4EALDH1A1 | |
| SCHEMBL14127790 | 0.76 | KCNH2 (0.48) | MAPTRAB9AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1589145-A | Alpha v integrin receptor antagonists | MERCK & CO INC (US) | 2005-03-02 | — | — | CN | disclosed |